KR900008812B1 - A process for the preparation of 4-hydroxy-2-methyl-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides - Google Patents
A process for the preparation of 4-hydroxy-2-methyl-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides Download PDFInfo
- Publication number
- KR900008812B1 KR900008812B1 KR1019830001097A KR830001097A KR900008812B1 KR 900008812 B1 KR900008812 B1 KR 900008812B1 KR 1019830001097 A KR1019830001097 A KR 1019830001097A KR 830001097 A KR830001097 A KR 830001097A KR 900008812 B1 KR900008812 B1 KR 900008812B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- benzothiazine
- hydroxy
- dioxide
- minutes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음.No content.
Description
본 발명은 진통, 소염작용을 가지는 다음 일반식(I)의 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복스아마이드-1,1-디옥사이드의 제조방법에 관한 것이다.The present invention provides a method for preparing 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide of the following general formula (I) having analgesic and anti-inflammatory action It is about.
상기식에서, R은 페닐; 할로겐(C1, Br 또는 I) 또는 C1-C6알킬 그룹으로 치환된 아릴; 비치환되거나 할로겐(Cl, Br 또는 I) 또는 C1-C6알킬 그룹으로 치환된 또는 2,3 또는 4-피리딜; 5-메틸-이속사졸릴 또는 2-티아졸릴이다.Wherein R is phenyl; Aryl substituted with halogen (C1, Br or I) or C 1 -C 6 alkyl group; Unsubstituted or substituted with halogen (Cl, Br or I) or C 1 -C 6 alkyl group or 2,3 or 4-pyridyl; 5-methyl-isoxazolyl or 2-thiazolyl.
이러한 생성물중, 특히 치료효과가 탁월한 화합물을 다음 일반식(II)의 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복스아마이드-1,1-디옥사이드이다.Among these products, particularly compounds having excellent therapeutic effects are 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide of the following general formula (II).
본 발명의 일반식(I) 화합물은 다음 일반식(III)의 알킬 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복실레이트-1,1-디옥사이드를 다음 일반식(IV)의 마그네슘 유도체와 반응시켜 제조한다.General formula (I) compound of this invention is alkyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide of following general formula (III) Prepared by reaction with a magnesium derivative of formula (IV).
R-NH-Mg-X (IV)R-NH-Mg-X (IV)
상기식에서, R1은 C1-C6알킬 그룹이고, X는 할로겐, 바람직하게는 Br이고, R은 일반식(I)에서 정의한 것과 같다.Wherein R 1 is a C 1 -C 6 alkyl group, X is halogen, preferably Br, and R is as defined in formula (I).
이 반응은 반응에 불활성인 용매중에서 0 내지 130℃의 온도에서 반응이 거의 완결될때까지 수행한다. 얻어진 중간체는 산 매체중에서 가수분해하여, 일반식(I)의 화합물을 얻고, 이것을 재결정시킨다This reaction is carried out until the reaction is almost complete at a temperature of 0 to 130 ° C. in a solvent inert to the reaction. The obtained intermediate is hydrolyzed in an acid medium to obtain a compound of formula (I), which is then recrystallized.
본 발명에 따라, 일반식(II)의 4-하이드록시-2-메틸-N-(2-피리딜)-2H-1,2-벤조티아진-3-카복스아마이드-1,1-디옥사이드는 일반식(V)의 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복실레이트-1,1-디옥사이드(일반식(III)에서 R1이 -CH2-CH3일 경우)를 일반식(VI)의 2-아미노피리딜-마그네슘 브로마이드(일반식(IV)에서 R이일 경우)와 반응에 불활성인 용매중에서 반응시키고, 다음에 얻어진 중간체를 산 매체중에서 가수분해하여 일반식(II)의 화합물을 제조하는데, 이는 다음 반응식으로 나타낼 수 있다.According to the invention, 4-hydroxy-2-methyl-N- (2-pyridyl) -2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide of general formula (II) Is 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide of formula (V) wherein R 1 in formula (III) is -CH 2- CH 3 ) is 2-aminopyridyl-magnesium bromide of formula (VI) (R in formula (IV) In a solvent inert to the reaction, and then the obtained intermediate is hydrolyzed in an acid medium to produce a compound of formula (II), which can be represented by the following scheme.
이 반응은 바람직하게는 0°내지 130℃에서 생성물(V)와 (VI) 키실렌-테트라하이드로푸란(THF) 혼합물중에서 1 내지 8시간동안 불활성 대기중에서 교반하여 수행한다. 반응은 예를들면 환류 온도에서 행할 수 있다.This reaction is preferably carried out by stirring in an inert atmosphere for 1 to 8 hours in a mixture of product (V) and (VI) xylene-tetrahydrofuran (THF) at 0 ° to 130 ° C. The reaction can be carried out, for example, at reflux temperature.
출발생성물(V)는 다음 문헌[참조 : J.Org.Chem.2241(1965) 및 미합중국 특허 제 3,501,466호]에 기술된 공정으로 제조할 수 있고, 생성물(VI)는 아직 문헌에 기술되어 있지는 않으나, 다음 문헌[참조 : VOGEL의 "Text-book of practicla organic chemistry", 1124페이지, 4 th Edition]에 기술된 공정과 유사한 공정으로 이는 아래 도표에서 표시한 바와같이 제조할 수 있다.The starting product (V) can be prepared by the process described in J. Org. Chem. 2241 (1965) and US Pat. No. 3,501,466, and product (VI) is not yet described in the literature. , A process analogous to that described in the VOGEL "Text-book of practicla organic chemistry", page 1124, 4 th Edition, which can be prepared as indicated in the table below.
[실시예 1]Example 1
a) 질소 유입구, 환류 냉각기 및 패널이 장치된 3구 플라스크에 1g(0.04몰)의 Mg, 3.5ml (0.04몰)의 에틸브로마이드 및 25ml의 THF를 가하고, 실온에서 교반한다. 이 반응은 발열 반응이므로, 환류후에도 반응 자체로 인해, 10분간 가열한다. 그후 반응 용액을 냉각하고 25ml의 THF중에서 용해된 4.0g(0.043몰)의 2-아미노피리딘을 15분에 걸쳐 적가한 후, 30분간 교반시킨다.a) 1 g (0.04 mol) Mg, 3.5 ml (0.04 mol) ethyl bromide and 25 ml THF are added to a three necked flask equipped with a nitrogen inlet, reflux cooler and panel and stirred at room temperature. Since this reaction is exothermic, the reaction itself is heated for 10 minutes even after reflux. The reaction solution is then cooled and 4.0 g (0.043 mol) of 2-aminopyridine dissolved in 25 ml of THF is added dropwise over 15 minutes, followed by stirring for 30 minutes.
b) N2유입구와 환류 냉각기 및 깔대기가 장치된 3구 플라스크에, 100ml의 키실렌중에 용해된 일반식(V)의 출발생성물 5.7g을 가하고, 비등할때까지 가열한다.b) To a three-necked flask equipped with an N 2 inlet, reflux condenser and funnel, add 5.7 g of the starting product of formula (V) dissolved in 100 ml of xylene and heat until boiling.
그후, 상기 실시예에서 제조된 일반식(VI) 생성물의 용액을 30분에 걸쳐, 환류를 계속하면서 적가하는데, 적가가 끝날 무렵에서 2시간동안 환류, 교반시킨다.Thereafter, the solution of the general formula (VI) product prepared in the above example was added dropwise over 30 minutes while continuing reflux, at which point it was refluxed and stirred for 2 hours at the end of the dropwise addition.
이동안에 황색 고무상의 물질이 생성된다. 2 1/2시간후에, 반응액을 냉각시키고 경사한다. 잔사를 1N 염산으로 가수분해하면 황색 고무상 물질은 조 고체로 되는데 이를 여과하고, 건조시킨 후 물에 현탁시키고 30분간 교반시킨다. 황색의 침전이 생성되면 여과하여 융점 198 내지 200℃의 일반식(II) 화합물 3.3g (수율=50%)을 얻는다. 이소프로파놀로 재결정하여 분석용 시료를 얻는다.Yellow rubbery material is produced in the migration. After 2 1/2 hours, the reaction solution is cooled and decanted. Hydrolysis of the residue with 1N hydrochloric acid gives the yellow gummy material a crude solid which is filtered off, dried and then suspended in water and stirred for 30 minutes. Filtration gave a yellow precipitate, which gave 3.3 g (yield = 50%) of the compound of formula (II) having a melting point of 198 to 200 캜. Recrystallized with isopropanol to obtain a sample for analysis.
칼 피셔 방법에 따른 수분 함량은 0.1%이며 KBr 타브렛에서의 적외선 스팩트럼 근사 흡수대는 3340, 1635, 1580, 1530, 1440, 1355, 1305, 1185cm-1이다.The moisture content according to Karl Fischer method is 0.1% and the infrared spectrum approximate absorption bands in KBr tablets are 3340, 1635, 1580, 1530, 1440, 1355, 1305, 1185 cm-1.
[실시예 2]Example 2
a) N2유입구, 환류 냉각기 및 깔대기가 장치된 3구 플라스크에 1g(0.04몰)의 Mg을 가하고 20ml의 테이트라하이드로푸란에 용해된 3.5ml(0.04몰)의 에틸브로마이드를 깔대기를 넣고 25분 가량에 걸쳐 Mg에 적가한 후, 혼합물을 실온에서 10분간 교반하고 50℃에서 30분간 가열한다. 다음에 반응혼합물을 냉각시키고, 20ml의 테트라하이드로푸란에 용해된 4g(0.043몰)의 2-아미노피리딘을 가한후, 15분간 교반시킨다.a) Add 1 g (0.04 mol) of Mg to a 3-necked flask equipped with an N 2 inlet, reflux condenser and funnel, add funnel with 3.5 ml (0.04 mol) of ethyl bromide dissolved in 20 ml of tetrahydrofuran and 25 minutes. After dropwise addition to Mg over a portion, the mixture is stirred at room temperature for 10 minutes and heated at 50 ° C. for 30 minutes. Next, the reaction mixture was cooled, 4 g (0.043 mol) of 2-aminopyridine dissolved in 20 ml of tetrahydrofuran was added, followed by stirring for 15 minutes.
b) N2유입구와 환류 냉각기 및 판넬이 장치된 250ml들이 3구 플라스크에 50ml의 키실렌에 용해된 5.42g의 메틸 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복실레이트를 100℃에서 용해시킨다. 상기에서 제조한 마그네슘 용액을 유욕상에서 환류시키면서 1 1/2시간동안 가열하면서 30분에 걸쳐 차후에 제조한 용액에 적가한다. 다음에 혼합물을 냉각시키고, 용매를 경사하여 제거한다. 생성된 중간체는 고무상 물질인데 여기에 100ml의 1N 염산을 가하고, 45분간 교반하고, 여과한다. 수득된 조 생성물을 80ml의 수중에 교반시키면서 현탁시켜, 황색 고상 침전물을 수득하고, 여과시켜 모은다.b) 5.42 g of methyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3 dissolved in 50 ml of xylene in a 250 ml three necked flask equipped with N 2 inlet, reflux cooler and panel The carboxylate is dissolved at 100 ° C. The magnesium solution prepared above is added dropwise to the solution prepared subsequently over 30 minutes while heating for 1 1/2 hours while refluxing in an oil bath. The mixture is then cooled and the solvent is decanted off. The resulting intermediate is a rubbery substance, to which 100 ml of 1N hydrochloric acid is added, stirred for 45 minutes, and filtered. The crude product obtained is suspended with stirring in 80 ml of water to give a yellow solid precipitate which is collected by filtration.
디클로로메탄-메탄올중의 황색고체를 재결정하여 융점 198 내지 200℃의 생성물 4g을 얻는다. 이 고체는 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복스아마이드-1,1-디옥사이드이다.The yellow solid in dichloromethane-methanol is recrystallized to give 4 g of product having a melting point of 198 to 200 ° C. This solid is 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide.
KBr 타브렛에서의 적외선 스펙트럼 근사 흡수대는 3340, 1635, 1580,1530, 1440, 1355, 1305, 1185cm-1이다.Infrared spectrum approximate absorption bands in KBr tablets are 3340, 1635, 1580, 1530, 1440, 1355, 1305, 1185 cm −1 .
[실시예 3]Example 3
a) N2유입구와 환류냉각기 및 판넬이 장치된 100ml들이 3구 플라스크에 1g(0.04몰)의 Mg을 넣고, 20ml의 테트라하이드로푸란에 용해된 3.5g(0.04몰)의 에틸 브로마이드를 깔대기에 넣고 25분에 걸쳐 Mg에 적가한 후, 적가가 끝나면 실온에서 교반한 후, 50℃에서 30분간 가열한다. 혼합물을 냉각후, 20ml의 테트라하이드로 푸란에 용해된 4g(0.043몰)의 아닐린을 20분에 걸쳐 적가한다. 적가가 끝나면 혼합물을 15분간 교반시킨다.a) 1 g (0.04 mole) Mg was added to a 100 ml three-necked flask equipped with an N 2 inlet, reflux condenser and panel, and 3.5 g (0.04 mole) ethyl bromide dissolved in 20 ml of tetrahydrofuran was added to the funnel. After dropwise addition to Mg over 25 minutes, after the dropwise addition, the mixture was stirred at room temperature and then heated at 50 ° C for 30 minutes. After cooling the mixture, 4 g (0.043 mol) of aniline dissolved in 20 ml of tetrahydrofuran are added dropwise over 20 minutes. After the addition, the mixture is stirred for 15 minutes.
b) N2유입구와 환류 냉각기 및 판넬이 장치된 250ml들이 3구 플라스크에서 5.7g의 에틸 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복실레이트를 100℃에서 50ml의 키실렌에 용해시킨다. 상기에서 제조한 그리나드 시약(Grignard's reagent)을 차후에 제조된 용액에 30분에 걸쳐 적가하고, 유욕중에서 환류시키면서 1 1/2시간동안 가열한다. 이 액을 냉각하고, 용매를 경사시켜 제거한다.b) 5.7 g of ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate at 100 ° C. in a 250 ml three necked flask equipped with N 2 inlet, reflux condenser and panel. Dissolve in 50 ml of xylene. The Grignard's reagent prepared above is added dropwise to the solution prepared over 30 minutes, and heated for 1 1/2 hours while refluxing in an oil bath. This liquid is cooled and the solvent is decanted to remove.
생성된 중간체는 고무상인데 여기에 100ml의 1N 염산을 가한후, 45분간 교반시키고 여과하여 조 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복시아닐리드-1,1-디옥사이드를 얻는다. 이를 디클로로메탄-메탄올로 재결정하여 융점 210°내지 213℃의 순수한 생성물 2.1g(수율 30%)을 얻는다. 이소프로파놀로 재결정하여 분석용 시료를 얻는다.The resulting intermediate was rubbery, to which 100 ml of 1N hydrochloric acid was added, stirred for 45 minutes and filtered to give crude 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxycyanide-1, Obtain 1-dioxide. This was recrystallized from dichloromethane-methanol to obtain 2.1 g (yield 30%) of pure product having a melting point of 210 ° to 213 ° C. Recrystallized with isopropanol to obtain a sample for analysis.
[실시예 4]Example 4
a) N2유입구와 환류 냉각기 및 깔대기가 장치된 100ml 들이 3구 플라스크에 1g의 Mg(0.04몰)을 넣고, 20ml의 테트라하이드로푸란에 용해된 3.5ml(0.04몰)의 에틸 브로마이드를 깔대기에 넣는다. 용액을 약 25분 동안에 걸쳐 Mg에 적가하고, 적가가 끝나면 10분간 실온에서 교반시킨 후 30분동안 50℃에서 가열한다. 혼합물을 냉각시킨 후 20ml의 테트라히이드로푸란에 용해된 4.2g(0.043몰)의 3-아미노-5-메틸-이속사졸을 가하고 15분간 교반한다.a) 1 g of Mg (0.04 mol) is placed in a 100 ml three-necked flask equipped with an N 2 inlet, reflux cooler and funnel, and 3.5 ml (0.04 mol) of ethyl bromide dissolved in 20 ml of tetrahydrofuran is added to the funnel. . The solution is added dropwise to Mg over about 25 minutes, and after the addition, the solution is stirred at room temperature for 10 minutes and then heated at 50 ° C. for 30 minutes. After the mixture was cooled, 4.2 g (0.043 mol) of 3-amino-5-methyl-isoxazole dissolved in 20 ml of tetrahydrofuran were added and stirred for 15 minutes.
b) N2유입구와 환류냉각기 및 깔대기가 장치된 3구 플라스크에서 5.7g의 에틸 4-하이드록시-2-메틸-2H-1,2-벤조티아진-3-카복실레이트를 100℃에서 50ml의 키실렌에 용해시킨다. 상기에서 제조한 마그네슘 용액을 차후에 제조된 위 용액에 30분에 걸쳐 적가하고, 유욕상에서 환류하에 1 1/2시간동안 가열한다. 이 액을 냉각시키고 용매를 경사시켜 제거한다. 생성된 중간체는 고무상인데, 여기에 100ml의 1N 염산을 가한다. 15분간 교반한후, 여과하여 회색의 4-하이드록시-2-메틸-N-(5-메틸-이속사졸릴)-2H-1,2-벤조티아진-3-카복스아마이드-1,1-디옥사이드를 얻는다. 디클로로메탄-메탄올로 재결정하여 융점 250-252℃의 순수한 생성물을 얻는다.b) 50 ml of 5.7 g of ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate at 100 ° C. in a three necked flask equipped with an N 2 inlet, reflux cooler and funnel. Dissolve in xylene. The magnesium solution prepared above is added drop wise to the prepared solution above over 30 minutes and heated for 1 1/2 hours under reflux on an oil bath. The solution is cooled and the solvent is decanted to remove it. The resulting intermediate is rubbery, to which 100 ml of 1N hydrochloric acid is added. After stirring for 15 minutes, it was filtered to obtain gray 4-hydroxy-2-methyl-N- (5-methyl-isoxazolyl) -2H-1,2-benzothiazine-3-carboxamide-1,1 Obtain dioxide. Recrystallization from dichloromethane-methanol gives the pure product at melting point 250-252 ° C.
Claims (4)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES511,472 | 1982-04-16 | ||
ES511472A ES8300760A1 (en) | 1982-04-16 | 1982-04-16 | Manufacture of 4-hydroxy-2-methyl-2h-1,2- benzothiazine-3-carboxamide-1,1-dioxides |
ES518908A ES8404788A2 (en) | 1983-01-11 | 1983-01-11 | Hydroxy methyl 2h-benzothiazine carboxamide di:oxide prepn. |
ES518,909 | 1983-01-11 | ||
ES518,908 | 1983-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR840004094A KR840004094A (en) | 1984-10-06 |
KR900008812B1 true KR900008812B1 (en) | 1990-11-30 |
Family
ID=26156040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019830001097A KR900008812B1 (en) | 1982-04-16 | 1983-03-18 | A process for the preparation of 4-hydroxy-2-methyl-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR900008812B1 (en) |
-
1983
- 1983-03-18 KR KR1019830001097A patent/KR900008812B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR840004094A (en) | 1984-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0091464A1 (en) | Method for the preparation of cyano-heterocycles. | |
US4116964A (en) | 2-[(N-2-pyridylcarbamoyl)methyl]saccharin | |
EP0262873B1 (en) | N-tetrazolyl thiazolecarboxamide derivatives and their use | |
FI72719C (en) | SYNTESFOERFARANDE FOER PIROXIKAM SAMT MELLANPRODUKT. | |
US4478996A (en) | Process for the preparation of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides | |
KR900008812B1 (en) | A process for the preparation of 4-hydroxy-2-methyl-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides | |
JP2668816B2 (en) | Process for producing benzothiadiazole derivative | |
JP3440196B2 (en) | Method for producing thiobenzamide derivative | |
KR940003759B1 (en) | Process for the preparation of 4-oh qunoline carboxylic acid derivatives | |
JPH0144708B2 (en) | ||
RU2155765C2 (en) | 1,4-fihydropyridine derivatives with cyclic bridge in positions 1,2 in the form of mixture of their isomers | |
KR880000154B1 (en) | The method of preparation for amino-nitro pyridine | |
WO2007060685A1 (en) | An improved process for the synthesis of quinoline derivatives | |
EP0062068B1 (en) | N-phthalidyl-5-fluorouracil derivatives | |
JPH0144707B2 (en) | ||
JPH0148267B2 (en) | ||
JPH0150702B2 (en) | ||
EP0412014A1 (en) | Benzothiazine derivatives, their preparation and their uses as medicines or as intermediates for the synthesis of medicines | |
US6333414B1 (en) | Process for the synthesis of trisubstituted oxazoles | |
KR0159511B1 (en) | New quinoline derivatives and their process | |
KR840002103B1 (en) | Process for preparing carbostyril derivatives | |
JPS6044305B2 (en) | Method for producing 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides | |
JP4069201B2 (en) | Method for producing 4-hydroxythiazole derivative | |
JPS6249271B2 (en) | ||
JPS6159309B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 19990916 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |